Eli Lilly and Company $LLY Stock: Provenance Wealth Advisors LLC Boosts Holdings

Provenance Wealth Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 5,300.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,350 shares of the company’s stock after buying an additional 1,325 shares during the period. Provenance Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,562,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ackerman Capital Advisors LLC increased its holdings in Eli Lilly and Company by 19.7% in the third quarter. Ackerman Capital Advisors LLC now owns 322 shares of the company’s stock valued at $373,000 after purchasing an additional 53 shares during the period. One Day In July LLC lifted its holdings in Eli Lilly and Company by 1.6% during the 3rd quarter. One Day In July LLC now owns 567 shares of the company’s stock worth $656,000 after buying an additional 9 shares during the period. Hughes Financial Services LLC lifted its holdings in Eli Lilly and Company by 6.3% during the 3rd quarter. Hughes Financial Services LLC now owns 471 shares of the company’s stock worth $545,000 after buying an additional 28 shares during the period. TrinityBridge Ltd lifted its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. TrinityBridge Ltd now owns 40,000 shares of the company’s stock worth $46,405,000 after buying an additional 101 shares during the period. Finally, Lyell Wealth Management LP grew its position in shares of Eli Lilly and Company by 2.4% in the 3rd quarter. Lyell Wealth Management LP now owns 2,914 shares of the company’s stock valued at $3,372,000 after buying an additional 67 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Morgan Stanley lifted their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price for the company in a research note on Tuesday, September 15th. HSBC lifted their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $1,450.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,404.14.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 18,500 shares of company stock worth $22,970,770. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $1,418.14 on Thursday. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,449.68. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 46.03, a PEG ratio of 1.76 and a beta of 0.40. The company’s fifty day moving average price is $1,207.75 and its two-hundred day moving average price is $1,097.85. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm posted $7.02 earnings per share. On average, analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A report says Cantor Fitzgerald raised its price target to $1,600 from $1,440 and kept an “overweight” rating, adding to analyst optimism. Cantor Fitzgerald price-target update
• Positive Sentiment: Lilly advanced a next-generation obesity treatment into a Phase 3 study. Further progress could strengthen its pipeline beyond current weight-loss drugs, although the report provides limited trial details. Lilly advances Phase 3 obesity study
• Positive Sentiment: ETFs reportedly bought about $105 million of LLY shares on Nov. 2, suggesting institutional fund demand that may support the stock. ETF purchases of Lilly shares
• Positive Sentiment: In a challenge brought by Lilly, the National Advertising Division recommended that Good Life Meds stop or revise certain claims about compounded tirzepatide products. The recommendation could help Lilly contest marketing by compounded-drug competitors. Advertising claims recommendation
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale is notable, though the planned nature makes it less clear as a signal about the company’s outlook. Insider sale report
• Negative Sentiment: Recent commentary questions the quality and durability of Lilly’s growth, citing possible one-off revenue benefits and lower realized prices. With expectations and valuation elevated, any deceleration could pressure the shares. Revenue growth quality concerns

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.